X
Dec 08, 2021 10:44 AM (GMT+8) · EqualOcean
Wuhan abclonal Biotechnology Co., Ltd., a provider of solutions for life science tool industry, recently completed a round D financing of RMB 1.2 billion after completing round C financing of RMB 600 million in 2020. This round of financing is jointly led by Sequoia China, Luxin venture capital and CMB international capital, followed by many institutions such as zhengxingu capital and Beijing Taikang investment. After this round of financing, aibotec will continue to expand its investment in R & D and platform construction in the three sectors of antibody, molecular enzyme reagent and cro antibody discovery, continue to integrate the world's leading technology and team, and gradually build a comprehensive supplier of one-stop solutions for "reagent + cro service + equipment and automation" in the field of life science tools.

This text is a result of machine translation.